ArticleInternational journal of molecular sciences2024
Leukocyte Telomere Length as a Marker of Chronic Complications in Type 2 Diabetes Patients: A Risk Assessment Study.
Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Epigenetic regulation in type II diabetes: linking molecular mechanisms to clinical management.Journal of diabetes and metabolic disorders · 2026Review
- Associations of Multiomics Biological Aging With Diabetic Retinopathy and Life Expectancy.Investigative ophthalmology & visual science · 2026Article
- Biological age acceleration, genetic susceptibility, and incident diabetic retinopathy risk: A prospective cohort study.The journal of nutrition, health & aging · 2026Article
- Metformin exhibits gender specific impact on telomere dynamics by enhancing RAP1 expression in type-2 diabetes mellitus.Acta diabetologica · 2026Article
- Article
- The novel nutritional metabolic risk index and established triglyceride-glucose indices in type 2 diabetes: modifying role of biological aging assessed by telomere length.Frontiers in nutrition · 2026Article
- Circulating Bacterial DNA as a Novel Blood-Based Biomarker in Type 2 Diabetes Mellitus (DM2): Results from the PROMOTERA Study.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Telomere shortening has been linked to type 2 diabetes (T2D) and its complications. This study aims to determine whether leukocyte telomere length (LTL) could be a useful marker in predicting the onset of complications in patients suffering from T2D. Enrolled study subjects were 147 T2D patients. LTL was measured using a quantitative PCR method. Key subject's demographics and other clinical characteristics were also included. T2D patients with the shortest LTL had higher TC and non-HDL levels, compared to subjects with the longest LTL (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.